Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
(9) Renal impairment measured as an estimated glomerular filtration rate less than 15 ml min 1.73 m 2
A
Retatrutide remains an investigational compound in Phase 3 clinical trials and is not approved by Health Canada for human or veterinary use
By targeting multiple hormonal pathways, tirzepatide may support reduced caloric intake and improved metabolic response in eligible patients
US$ 28.62
US$ 20.71
US$ 25.97
US$ 20.55
US$ 25.95
US$ 29.17
US$ 23.86
